Medical Information Only. Consult your healthcare provider before considering clinical trial enrollment.

ClinicalTrials.gov 3 recruiting now early-phase tilt small index

Advanced Urothelial Carcinoma: early-phase trial registry

3 of 6 indexed Advanced Urothelial Carcinoma trials are currently recruiting, with more weight in Phase 1-2.

Corpus placement: #2,866 of 28,707 conditions by registered trial count.

6 US clinical trials · 3 currently recruiting · #2,866 of 28,707 conditions by registered trial count

Advanced Urothelial Carcinoma: 6 US clinical trials tracked, 3 recruiting.

Advanced Urothelial Carcinoma is the subject of 6 registered US clinical trials on ClinicalTrials.gov, 3 of them currently open to new participants. 0 are in Phase 3-4 (later-stage) and 5 in Phase 1-2 (earlier-stage). The most active sponsor is Fujifilm Pharmaceuticals U.S.A., running 1 of these trials.

Enrollment posture brief

Registry condition advanced-urothelial-carcinoma

OPEN 3 | RECR 50% | LATE 0 | EARLY 5 | RANK #2866 | SPON 1

Nearest open-share peer: Achalasia (50% recruiting · 8 trials)

Acute Hypoxemic Respiratory 66.7%Abdominal Aortic Aneurysms50%Acupuncture50%Acute Lymphoblastic Leukemia50%Advanced Urothelial Carc (th…50%
Open-enrollment share among volume-matched conditions near Advanced Urothelial Carcinoma

Advanced Urothelial Carcinoma lists 3 open slots (50% of 6 indexed trials). Peers are matched on registered volume, not therapeutic-area browse lists. How peer matching works →

Key findings

What ClinicalTrials.gov does not surface for Advanced Urothelial Carcinoma on its own pages , computed from the registry mirror as of 2026-08-08. Each line carries its own denominator so it can be quoted as it stands.

  1. Advanced Urothelial Carcinoma is recruiting above its size-band peers.

    3 of 6 indexed trials (50%) are open to enrollment, against a 46.5% average across 27,806 conditions with fewer than 20 trials. The peer set uses the same ClinicalTrials.gov-derived counts as this page.

  2. One sponsor concentrates Advanced Urothelial Carcinoma research.

    Fujifilm Pharmaceuticals U.S.A. accounts for 1 of 6 trials (16.7%). 6 distinct sponsors appear on at least one study for this condition label.

  3. Typical Advanced Urothelial Carcinoma enrolment sits around 120 participants.

    Median target enrolment is 120 among the 6 trials that report a genuine target (sentinel values excluded). 2 of those (33.3%) plan for fewer than 100 participants.

  4. Advanced Urothelial Carcinoma research is mostly interventional.

    6 interventional and 0 observational studies make up this index (100% interventional). Study type is sponsor-reported on ClinicalTrials.gov.

Phase 12Phase 23

Phase Distribution

PhaseTrial count
Phase 1 2
Phase 2 3

Named interventions

Most-linked intervention names on Advanced Urothelial Carcinoma records (sponsor-reported on ClinicalTrials.gov). Counts are trial links, not unique products.

Pembrolizumab Drug
2 trials
StrataNGS Device
1 trials
Systemic therapy Other
1 trials
FF-10832 Drug
1 trials
Eribulin Mesylate Drug
1 trials
Pharmacological Study Other
1 trials
Gemcitabine Hydrochloride Drug
1 trials
Devimistat Drug
1 trials

US sites by state

Facility locations filed on Advanced Urothelial Carcinoma trials. A trial with sites in several states counts in each.

California 4 trials
Illinois 3 trials
Tennessee 2 trials
Pennsylvania 2 trials
Ohio 2 trials
New York 2 trials
Texas 1 trials
South Dakota 1 trials

Source: ClinicalTrials.gov, National Library of Medicine. Data is informational only.

What to do with this Advanced Urothelial Carcinoma page

6 registered trials, 3 currently recruiting, is a starting point for a conversation, not a diagnosis or a recommendation.

Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This Advanced Urothelial Carcinoma condition card totals 6 registered trials; most-linked intervention Pembrolizumab; top US site state California. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.